Psilocybin Shows Promise as Single-Dose Treatment for Cocaine Addiction in Clinical Trial

The Breakthrough in Addiction Treatment

Results from a new clinical trial published in JAMA Network Open this month show that a single dose of psilocybin could be an effective treatment for cocaine addiction. The study found that 19 participants who received psilocybin were more likely to abstain from cocaine than 17 participants who received a placebo of diphenhydramine, a common antihistamine.

Participants in both groups worked with therapists to process their experiences, highlighting the importance of the therapeutic context alongside the medication.

The Urgent Need for Cocaine Addiction Treatments

Dr. Peter Hendricks, a behavioral health professor at the University of Alabama at Birmingham and lead author of the study, emphasized the critical need for effective treatments. Currently, there are no FDA-approved medications for addiction to cocaine or other stimulants like methamphetamine.

Overdoses involving stimulants are killing more Americans, and according to the latest UN global drug report, cocaine deaths are rising globally as cocaine production reaches an all-time high.

Understanding the Mechanism

Experts believe psilocybin works by increasing neuroplasticity and psychological plasticity – the ability to change thinking and behavior. Addictions inherently involve resistance to changing rigid, impulsive behaviors, which psychedelics may help overcome.

Unlike traditional addiction medications that target the same neurochemical systems as the substance itself, psilocybin produces a profound altered state of consciousness within a structured psychotherapy context. It acts more like a catalyst within a therapeutic process rather than a maintenance medication.

Addressing Cocaine Withdrawal Symptoms

Cocaine withdrawal symptoms are primarily psychological rather than physically painful, including bad dreams, agitation, depression, and cravings. This psychological nature may make psilocybin particularly effective for cocaine addiction, as it can facilitate shifts in perspective and self-compassion that help people change their behavior.

The therapeutic framework allows individuals to process their experiences and develop new insights about their addiction patterns, potentially breaking the cycle of craving and use.

Diverse Clinical Trial Participation

This study is notable as the first psychedelic clinical trial to include a majority of Black participants. While many spiritual rituals involving psychedelics originated in Indigenous societies in Latin America and Africa, US psychedelic culture today is often associated with Silicon Valley and elite, white personalities.

Dr. Hendricks specifically recruited participants who were dependent on cocaine and wanted to stop, rather than advertising for psychedelic enthusiasts. This approach likely reduced the "expectation effect" and produced more generalizable results.

Future Research Directions

A critical commentary published alongside the study noted that the results might not be generally applicable because the study excluded people with comorbid depression and anxiety. However, experts point out that psilocybin shows promise for treating both conditions.

The success of this trial is a clear indication that psilocybin for cocaine use disorder is a promising treatment that should proceed to larger-scale clinical trials. As research continues, the medical community may gain more insight into how psychedelics can be integrated into addiction treatment protocols.